Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...

Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $8 price target The firm believes Adial has the potential to outperform over the next 12 months, saying its ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 78,900 shares, a ...

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of ...

Short interest in Adial Pharmaceuticals Inc (NASDAQ:ADIL) decreased during the last reporting period, falling from 77.82K to 51.17K. This put 0.82% of the company's publicly available shares short.

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ADIL) has announced the publication of a peer-reviewed article in the European Journal of Internal Medicine, which... ByInvesting.com • 10 ...

As of 11:10 AM EST. Market Open.